A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients.
FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.
A study shows ZEB2 has clinical potential and may improve TNM risk-stratification and guide treatment in colorectal cancer.
A study of an equal-access military health system shows universal health insurance for both the military and civilian populations could improve CRC screening rates.
Plasma fibrinogen tests should be encouraged routinely in clinical practice to clarify its predictive benefit, according to a study.
A study shows undergoing treatment for DLBCL at a clinic with more experience was linked with important clinical outcomes.
Minimal residual disease negativity measured by next-generation sequencing was a valuable prognostic biomarker for multiple myeloma.
The percentage of patients with pediatric melanoma is 6-fold to the 28-fold higher when compared with the general population of patients with melanoma.
A study shows stress may affect certain cellular, cytokine, and chemokine markers in the body of patients with CLL.
A study shows treatment with ibrutinib is superior to chemoimmunotherapy for patients with chronic treatment-naive CLL.